The MASH market's potential can only be unlocked by a scalable, non-invasive diagnostic. Biopsies are not feasible for a 90-million-person potential market. Diagnostics are essential for identifying patients and monitoring the efficacy of expensive new treatments, a key requirement for all stakeholders.

To achieve an affordable price for its advanced cancer test, Delphi prioritizes algorithmic complexity over "wet lab" complexity. This strategy keeps physical sample processing simple and low-cost, putting the innovation into scalable software (AI/ML) to analyze the data, which is key for mass adoption.

There is a profound mismatch between the critical role of diagnostics in guiding medical treatment and their reimbursement value. This value gap highlights a systemic inefficiency and a major opportunity for companies that can demonstrate improved patient outcomes and system-wide savings.

General Catalyst's CEO highlights a core flaw in healthcare: insurance providers don't reimburse for longevity or preventative care because customers frequently switch plans, preventing insurers from capturing long-term ROI. The first company to solve this misalignment and make longevity "financeable" will unlock a massive market.

Function Health provides comprehensive lab testing with over 160 biomarkers, which would typically cost $15,000, for a $365 annual membership. This business model makes high-end, data-driven preventative care accessible to a much broader audience beyond the wealthy who can afford traditional concierge doctors.

Unlike traditional biotech VCs, Yosemite allocates a quarter of its fund to digital health. This reflects its mission to reduce cancer mortality across the entire patient journey, funding solutions for pricing transparency, financial toxicity, and post-approval care.

The traditional approach to cardiovascular disease is treating patients only after symptoms appear, by which point damage has occurred. Coursera Health's model is to intervene *before* biomarkers elevate, using early prediction and prevention to stop the cumulative damage that causes the disease, representing a fundamental paradigm shift in medicine.

By verticalizing infrastructure to offer at-home diagnostic testing for free or at cost, a healthcare company can build the world's largest health dataset. This loss leader provides immense value to patients, builds trust, and creates a powerful and defensible customer acquisition channel for high-margin treatments.

Instead of competing with advanced technologies like liquid biopsies or standard care, this breath test is positioned as a complementary first step. It serves as a valuable "enrichment layer" and risk stratification tool, which increases the prevalence of cancer in the group receiving downstream diagnostics, thereby making those subsequent tests more effective and cost-efficient.